Currently out of the existing stock ratings of Jami Rubin, 44 are a BUY (56.41%), 23 are a HOLD (29.49%), 11 are a SELL (14.1%).

Jami Rubin

Work Performance Price Targets & Ratings Chart

Analyst Jami Rubin, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 83.13% that have a potential upside of 36.93% achieved within 675 days.

Jami Rubin’s has documented 158 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 12-Dec-2025.

Wall Street Analyst Jami Rubin

Analyst best performing recommendations are on TEVA (TEVA PHARMA INDUSTRIES LTD ADR).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 11/6/2017. The price target of $13 was fulfilled within 11 days with a profit of $0.67 (5.43%) receiving and performance score of 4.94.

Average potential price target upside

of $45.74 (80.01%) on ABBV (ABBVIE).
of $26.14 (30.34%) on JNJ (JOHNSON & JOHNSON).
of $23.4 (62.82%) on BMY (BRISTOL-MYERS SQUIBB COMPANY).

ABBV AbbVie AGN Allergan plc BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson MRK Merck mpany MYL Viatris PRGO Perrigo Company PLC TEVA Teva Pharma Industries Ltd ADR LLY Eli Lilly and Company PFE Pfizer VTRS Viatris ALNY Alnylam Pharmaceuticals ZTS Zoetis

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score